U.S. markets close in 5 hours 6 minutes
  • S&P 500

    3,451.54
    +8.42 (+0.24%)
     
  • Dow 30

    28,344.53
    +35.74 (+0.13%)
     
  • Nasdaq

    11,554.18
    +37.68 (+0.33%)
     
  • Russell 2000

    1,621.27
    +3.56 (+0.22%)
     
  • Crude Oil

    40.86
    -0.84 (-2.01%)
     
  • Gold

    1,934.50
    +19.10 (+1.00%)
     
  • Silver

    25.36
    +0.39 (+1.54%)
     
  • EUR/USD

    1.1879
    +0.0051 (+0.43%)
     
  • 10-Yr Bond

    0.8090
    +0.0120 (+1.51%)
     
  • GBP/USD

    1.3166
    +0.0219 (+1.69%)
     
  • USD/JPY

    104.4010
    -1.0690 (-1.01%)
     
  • BTC-USD

    12,685.45
    +1,628.44 (+14.73%)
     
  • CMC Crypto 200

    253.76
    +8.87 (+3.62%)
     
  • FTSE 100

    5,803.92
    -85.30 (-1.45%)
     
  • Nikkei 225

    23,639.46
    +72.42 (+0.31%)
     

Hill-Rom Holdings: Q2 Earnings Insights

Benzinga Insights
·1 min read

 

Shares of Hill-Rom Holdings (NYSE:HRC) rose 0.7% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 12.28% over the past year to $1.28, which beat the estimate of $1.15.

Revenue of $723,200,000 rose by 1.26% from the same period last year, which beat the estimate of $701,640,000.

Outlook

Hill-Rom Holdings hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 01, 2020

View more earnings on HRC

Time: 11:04 AM ET

Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fir.hill-rom.com%2Fevents-and-presentations%2Fdefault.aspx&eventid=2160430&sessionid=1&key=809EC6984414C9917559138F3F7E9B07&regTag=&sourcepage=register

Recent Stock Performance

52-week high: $117.50

Company's 52-week low was at $72.29

Price action over last quarter: Up 5.32%

Company Profile

Hill-Rom Holdings Inc is a global provider of hospital equipment and medical supplies, including hospital beds for high- and low-acuity settings. Hill-Rom reports financial data across three operating segments: patient support systems (50% of fiscal 2018 sales), front-line care (34%), and surgical solutions (16%). The firm has significant operations internationally, with roughly 30% of revenue derived from international sources and the remaining 70% from its U.S. business.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.